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Abstract Objective: The Surviv-
ing Sepsis Campaign (SSC or ‘‘the
Campaign’’) developed guidelines for
management of severe sepsis and
septic shock. A performance
improvement initiative targeted
Intensive Care Med (2010) 36:222–231
DOI 10.1007/s00134-009-1738-3 ORIGINALchanging clinical behavior (process
improvement) via bundles based on
key SSC guideline recommendations
on process improvement and patient
outcomes. Design and setting: A
multifaceted intervention to facilitate
compliance with selected guideline
recommendations in the ICU, ED,
and wards of individual hospitals and
regional hospital networks was
implemented voluntarily in the US,
Europe, and South America. Ele-
ments of the guidelines were
‘‘bundled’’ into two sets of targets to
be completed within 6 h and within
24 h. An analysis was conducted on
data submitted from January 2005
through March 2008. Main results:
Data from 15,022 subjects at 165 sites
were analyzed to determine the
compliance with bundle targets and
association with hospital mortality.
Compliance with the entire resusci-
tation bundle increased linearly from
10.9% in the ﬁrst site quarter to
31.3% by the end of 2 years
(P\0.0001). Compliance with the
entire management bundle started at
18.4% in the ﬁrst quarter and
increased to 36.1% by the end of
2 years (P = 0.008). Compliance
with all bundle elements increased
signiﬁcantly, except for inspiratory
plateau pressure, which was high at
baseline. Unadjusted hospital mortal-
ity decreased from 37 to 30.8% over
2 years (P = 0.001). The adjusted
odds ratio for mortality improved the
longer a site was in the Campaign,
resulting in an adjusted absolute drop
of 0.8% per quarter and 5.4% over
2 years (95% CI, 2.5–8.4%). Con-
clusions: The Campaign was
associated with sustained, continuous
quality improvement in sepsis care.
Although not necessarily cause and
effect, a reduction in reported hospital
mortality rates was associated with
participation. The implications of this
study may serve as an impetus for
similar improvement efforts.
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Introduction
Severe sepsis accounts for 20% of all admissions to
intensive care units (ICUs) and is the leading cause of
death in non-cardiac ICUs, yet comprehensive clinical
practice guidelines had not existed [1, 2]. In 2002, hopeful
that outcomes of sepsis might be improved by standard-
izing care and informed by data from an increasing
number of clinical trials [3–10], the European Society of
Intensive Care Medicine (ESICM), the International
Sepsis Forum (ISF), and the Society of Critical Care
Medicine (SCCM) launched the Surviving Sepsis Cam-
paign (SSC or ‘‘the Campaign’’) [11]. Evidence-based
guidelines were developed through a formal and trans-
parent process [12–14]. The initial guidelines were
published in 2004 (endorsed by 11 professional societies);
an updated version was published in 2008 (involving 18
organizations comprising professional societies and
organized networks of hospitals).
The development and publication of guidelines often
do not lead to changes in clinical behavior and guidelines
are rarely, if ever, integrated into bedside practice in a
timely fashion [15–20]. The most effective means for
achieving knowledge transfer remains an unanswered
question across all medical disciplines [21, 22]. Recog-
nizing that implementing guidelines presents a signiﬁcant
challenge, the Campaign set out to develop and evaluate a
multifaceted model to change bedside practice to be
consistent with the recently published management
guidelines for patients with severe sepsis and septic
shock. A central part of that program was an international
registry into which providers could recruit and enter
patients and monitor their institution’s performance. This
analysis of the registry data describes the global initiative,
its implementation, and reports its impact on process
improvement and patient outcomes.
Methods
The SSC performance improvement initiative was laun-
ched in multiple sites internationally to measure changes
in the rates at which the sites achieved the targets of the
guideline bundles and to assess the impact of compliance
with the program on hospital mortality. The Campaign
activities included: the development of sepsis bundles;
creation of educational materials; recruitment of sites and
local physician and nurse champions through national and
international meetings; organization of regional launch
meetings where the initiative was introduced and educa-
tional materials presented; and the distribution of a secure
database application that allowed for data collection and
transfer, and offered a simple means for providing prac-
tice audit and feedback to local clinicians.
Guideline and bundle development
After the development of the evidence-based guidelines,
the SSC steering committee partnered with the Institute
for Healthcare Improvement (IHI) to develop a quality
improvement program to extend the Campaign guidelines
to the bedside management of severely septic and septic
shock patients [23, 24]. In partnership with IHI, key
elements of the guidelines were identiﬁed and organized
223into ‘‘bundles’’ of care [25, 26]. A two-phase approach
wasestablished,whichincludedthegenerationoftwosetsof
performance measures: the ﬁrst to be accomplished within
6 h of presentation with severe sepsis (the ‘‘resuscitation
bundle’’) and a second set to be accomplished within 24 h
(the ‘‘management bundle’’) (Fig. 1)[ 27, 28].
Sites and patient selection
Any hospital wishing to join the Campaign was eligible.
Participation was voluntary. Participant sites were
recruited at professional critical care congresses and
meetings, through the SSC and IHI Web sites, and by
interest generated from publication of the SSC guidelines.
Campaign symposia were regularly held at international
congresses and other venues between 2004 and 2008 to
increase awareness and participation. Local champions
and Campaign faculty were identiﬁed and trained to
develop regional and national networks.
Sites were encouraged to set up screening procedures
to identify patients with severe sepsis based on previously
established criteria [29]. Sites were provided a sample
screening tool in the Campaign manual and on the Web
site [30]. Participating sites were asked to screen for
patients in the emergency department (ED), the clinical
wards, and the ICU. Methods of screening were ulti-
mately established locally, and no effort to supervise the
quality or completeness of screening was attempted.
To be enrolled, a subject had to have a suspected site
of infection, two or more systemic inﬂammatory response
syndrome (SIRS) criteria [29], and one or more organ
dysfunction criteria. (See Supplemental Fig. 1 online.)
Clinical and demographic characteristics and time of
presentation with severe sepsis criteria were collected for
analysis of time-based measures. Time of presentation
was determined through chart review and deﬁned in
instructions to site data collectors on the Campaign Web
site and educational materials. For patients enrolled from
the ED, the time of presentation was deﬁned as the time
of triage. For patients admitted to the ICU from the
medical and surgical wards and for patients in the ICU
at the time of diagnosis, the time of presentation was
determined by chart review for the diagnosis of severe
sepsis.
Educational materials and resources
Educational materials available on the SSC Web site
included directions for implementing the bundles and
supporting data for each bundle element. A comprehen-
sive manual, Implementing the Surviving Sepsis
Campaign, was published in 2005 and included the data
collection tool in CD format [30]. The manual was also
distributed at meetings. It included protocols for partici-
pation and links to download the database. It also
reviewed issues related to ensuring consistency and
quality in data collection. The manual contents were
placed on the IHI and SSC Web sites. Cards and posters
of the two sepsis bundles (Fig. 1) were printed and widely
distributed.
During the course of the study period, initiation
meetings were held for participating hospital groups and
regional SSC launches, at which educational materials
were distributed, methods for data collection described,
institutional change concepts introduced, and examples of
implementation discussed. Ultimately, hospital-level
efforts and local protocol development were the purview
of individual improvement teams at each institution or
network. An e-mail list server with voluntary membership
was established to allow teams to collaborate across sites
by asking questions of their colleagues and to direct
communication from the SSC to sites. List members were
encouraged to share tools, protocols, and experiences.
Although no formal evaluation was in place to assess the
Severe Sepsis Bundles:
Sepsis Resuscitation Bundle
(To be accomplished as soon as possible and scored over first 6 hours): 
1. Serum lactate measured.
2. Blood cultures obtained prior to antibiotic administration.
3. From the time of presentation, broad-spectrum antibiotics administered within 3 hours for ED admissions and 1 hour for 
non-ED ICU admissions.
4. In the event of hypotension and/or lactate > 4 mmol/L (36 mg/dl): a) Deliver an initial minimum of 20 ml/kg of crystalloid 
(or colloid equivalent). b) Apply vasopressors for hypotension not responding to initial fluid resuscitation to
maintain mean arterial pressure (MAP) > 65 mm Hg.
5. In the event of persistent hypotension despite fluid resuscitation (septic shock) and/or lactate > 4 mmol/L (36 mg/dl):
a) Achieve central venous pressure (CVP) of > 8 mm Hg.
b) Achieve central venous oxygen saturation (ScvO2) of > 70%.*
Sepsis Management Bundle
(To be accomplished as soon as possible and scored over first 24 hours): 
1 Low-dose steroids administered for septic shock in accordance with a standardized hospital policy.
2 Drotrecogin alfa (activated) administered in accordance with a standardized hospital policy.
3 Glucose control maintained > lower limit of normal, but < 150 mg/dl (8.3 mmol/L).
4 Inspiratory plateau pressures maintained < 30 cm H2O for mechanically ventilated patients.
*Achieving a mixed venous oxygen saturation (SvO2) of 65% is an acceptable alternative.
© 2005 Surviving Sepsis Campaign and the Institute for Healthcare Improvement
Fig. 1 Resuscitation and
management bundles as
provided for Campaign
participants’ use
224quality of data entered, concern regarding this topic was
the second most frequently discussed area among par-
ticipants (following concern regarding roadblocks to
achieving physician engagement). Two of the authors
(CS and SRT) served as primary references for all
questions regarding data collection and entry throughout
the Campaign, and provided training for each site when
requested. A bi-monthly electronic newsletter was pub-
lished to share successes, strategies, and events.
Bundle targets and clinical outcomes
The primary outcome measure was change in compliance
with bundle targets over time. We deﬁned compliance as
evidence that allbundle elements were achieved withinthe
indicated time frame (i.e, 6 h for the resuscitation bundle;
24 h for the management bundle). As such, failure to
comply might occur either because of the failure of the
physiciantoattempttomeetthetargetorthefailuretoreach
the target despite the clinician’s attempt. Secondary out-
comemeasuresincludedhospitalmortality,hospitallength
of stay, and ICU length of stay. Ten performance measures
were established, based on the individual elements of the
resuscitation bundle and the management bundle.
Data collection
Data were entered into the SSC database locally at indi-
vidual hospitals into pre-established, unmodiﬁable ﬁelds
documenting performance data and the time of speciﬁc
actions and ﬁndings. Data on the local database contained
private health information (PHI) that enabled individual
sites to audit and review local practice and compliance as
well as provide feedback to clinicians involved in the
initiative. Data stripped of PHI were submitted every
30 days to the secure master SSC server at the Society of
Critical Care Medicine (Mount Prospect, Ill.) via ﬁle
transfer protocol (FTP) or as comma-delimited text ﬁles
attached to e-mail submitted to the Campaign’s server.
IRB approval
The global SSC improvement initiative was reviewed and
approved by the Cooper University Hospital Institutional
Review Board (Camden, NJ) as meeting criteria for
exempt status. Individual hospitals were encouraged to
refer to these documents and submit to their local IRBs
per local policy for documentation of exempt status or
waiver of consent. The US Department of Health and
Human Services’ Ofﬁce for Human Research Protections
clariﬁed that quality improvement activities such as SSC
often qualify for IRB exemption and do not require
individual informed consent [31].
Analysis set construction
The analysis set was constructed from the subjects entered
into the SSC database from its launch in January 2005
through March 2008. The a priori data analysis plan
limited inclusion to sites with at least 20 subjects and at
least 3 months of subject enrollment. Analysis presented
here was limited to the ﬁrst 2 years of subjects at each site
(Table 1).
Sites were characterized by: hospital size (\250, 250–
500, [500 beds); teaching status; ICU type (medical,
medical/surgical, other); and geographic region (Europe,
North America, South America). Subjects were charac-
terized by baseline severe sepsis information: location of
enrollment (ED, ICU, ward); site of infection (pulmonary,
urinary tract, abdominal, CNS, skin, bone, wound, cath-
eter, cardiac, device, other); acute organ dysfunction
(cardiovascular, pulmonary, renal, hepatic, hematologic).
Subject age and gender were not collected in deference to
country-speciﬁc privacy laws.
Data were organized by quarter through 2 years, with
the ﬁrst 3 months that a site entered subjects into the
database deﬁned as the ﬁrst quarter regardless of when
those months occurred from January 2005 through March
2008. Results are presented by site quarter, comparing the
initial quarter to the ﬁnal quarter for all sites and by
comparing the initial quarter to all subsequent quarters.
Because differences in bundle achievement and out-
comes could be confounded by changes in the
characteristics of subjects entered into the database, risk-
adjustment logistic regression models were constructed to
control for baseline subject characteristics. All baseline
characteristics present in the database were included in the
risk-adjustment models including location of enrollment,
acute organ dysfunctions, and site of infection. Site of
infection was reduced to pulmonary or non-pulmonary to
decrease the number of covariate patterns in the data and
increase the utility of the model residuals to assess model
ﬁt. Because the collection of some bundle elements was
conditioned on subject characteristics, different models
were constructed for each subpopulation. The model
assessing the base set of elements applicable to all subjects
(lactate measurement, blood culture before antibiotic
administration, broad spectrum antibiotic administration,
Table 1 Inclusion in database by quarter
Quarter Patients Sites
1 2,791 165
2 2,709 160
3 2,945 153
4 1,945 123
5 1,435 76
6 935 54
7 940 57
8 509 34
225and glucose control) included the baseline subject char-
acteristics as well as these elements. The model assessing
the administration of drotrecogin alfa in subjects with
multiple organ failures also included the baseline subject
characteristics and the base set of bundle elements. The
model assessing plateau pressure control in mechanically
ventilated subjects also included the baseline subject
characteristics and the base set of bundle elements. The
model assessing the administration of drotrecogin alfa,
low-dose steroids, CVP[8, and ScvO2[70 in subjects in
shock despite ﬂuids also included the baseline subject
characteristics and the base set of bundle elements.
To demonstrate that a decrease in hospital mortality
over time was not associated with entering less severely
ill patients in the database at individual sites, a logistic
regression model was constructed. It contained all sub-
jects entered over the maximum of 2 years of data
collection and the baseline subject characteristics for the
quarter of participation for up to eight quarters. Because
sites could enter the Campaign at any time, the possibility
that decreased hospital mortality over time was associated
with a global decrease in mortality for the same severity
of illness was investigated by constructing a logistic
regression model for hospital mortality using the ﬁrst
quarter of data collection from each site, including the
baseline subject characteristics and the calendar quarter (1
for the ﬁrst quarter of 2005 through 13 for the ﬁrst quarter
of 2008).
Statistical analysis
We compared raw rates including hospital mortality and
bundle compliance using Fisher’s exact test. We expres-
sed the effects of predictor variables on hospital mortality
using odds ratios, including 95% conﬁdence intervals for
risk-adjusted results. We assessed logistic regression
model ﬁt using the Hosmer–Lemeshow C statistic, the v
2
dispersion, the proportion of log-likelihood accounted for
by the model, and an examination of model residuals. We
constructed the databases in Access and FoxPro (Micro-
soft Corp., Redmond, WA) and conducted analyses in
DataDesk (Data Description, Ithaca, NY) and SAS (SAS
Institute, Cary, NC).
Results
Between January 2005 and March 2008, 15,775 subjects
at 252 qualifying sites were entered into the SSC database
(see Supplemental Table 1 online). Excluding hospitals
that contributed fewer than 20 subjects, the ﬁnal sample
consisted of 15,022 patients at 165 hospitals (a median of
57 and range of 20–471 subjects per hospital). Data from
up to eight quarters were analyzed from each site.
Hospitals contributed data for a mean duration of
15.6 months (median of 14 months). Table 2 includes site
and patient characteristics.
Change in achievement of bundle targets over time
Compliance rates for achieving all bundle targets over
time—both the overall bundles and the individual ele-
ments within both bundles—increased over time,
although both basal achievement rates and the magnitude
of improvement varied considerably across targets
(Table 3). Compliance with the initial 6-h bundle targets
increased linearly from 10.9% of subjects in the ﬁrst site
quarter to 31.3% by the end of 2 years in the campaign,
achieving statistical signiﬁcance by the second quarter
(10.9 vs. 14.9%, P\0.0001) (Fig. 2). The ability to
achieve the entire 24-h management bundle targets started
higher, at 18.4% in the ﬁrst quarter, and increased to
36.1% by the end of 2 years, but did not achieve statis-
tical signiﬁcance until the fourth quarter (18.4 vs. 21.5%,
P = 0.008).
Changes in hospital mortality
Unadjusted hospital mortality decreased from 37.0% in
the ﬁrst quarter in the Campaign to 30.8% by 2 years
(P = 0.001). On average, unadjusted mortality decreased
by 0.91% (95% CI 0.42–1.40%) for each quarter in the
Campaign. The results of the multivariable model
examining the effect of time in the Campaign on hospital
mortality are summarized in Table 4. The model ﬁt well
(Hosmer and Lemeshow C statistic of 18.1 with 18
degrees of freedom, P = 0.34 accounted for 36.6% of
variation in the data, with a v
2 dispersion of 1.04). In both
the unadjusted and adjusted models, the chance of death
decreased the longer a site was in the Campaign, resulting
in an adjusted absolute drop of 0.8% per quarter and 5.4%
over the ﬁrst 2 years (95% CI, 2.5–8.4%). In contrast, the
model examining the ﬁrst quarter of data from all sites did
not ﬁnd a secular trend, associated with calendar time, to
be signiﬁcantly associated with mortality (P = 0.23). The
model ﬁt well (Hosmer and Lemeshow C statistic of 16.6
with 18 degrees of freedom, P = 0.55, accounted for
18.4% of variation in the data, with a v
2 dispersion of
1.05).
Relationship between bundle targets and hospital
mortality
After adjustment for baseline characteristics, administra-
tion of broad-spectrum antibiotics (OR 0.86, 95% CI
0.79–0.93, P\0.0001), obtaining blood cultures before
their initiation (OR 0.76, 95% CI 0.70–0.83, P\0.0001),
226and maintaining blood glucose control (OR 0.67, 95% CI
0.62–0.71, P\0.0001) were all associated with lower
hospital mortality. Measuring lactate was not associated
with improved outcome (OR 0.97, 95% CI 0.90–1.05,
P = 0.48) (Table 5). The administration of drotrecogin
alfa in the ﬁrst 24 h was associated with improved sur-
vival in those with shock (OR 0.81, 95% CI 0.68–0.96,
P = 0.02). For those who required mechanical ventila-
tion, achieving plateau pressure control was associated
with improved outcome (OR 0.70, 95% CI 0.62–0.78,
P\0.0001). In those with septic shock, there was no
association between mortality and the use of low-dose
steroids, the ability to achieve a CVP C8 mmHg, or
demonstration of ScvO2 C70%.
Discussion
The Surviving Sepsis Campaign—a performance
improvement effort by hospitals across Europe, South
America, and the US—recruited the largest prospective
series of severe sepsis patients yet studied. The effort took
place in 30 countries, was voluntary (no sites or clinicians
were paid for data collection or for becoming part of the
Campaign), and was multidisciplinary, reﬂecting the
ethos of the founding professional societies. By instituting
a practice improvement program grounded in evidence-
based guidelines, SSC increased compliance with the
change bundles that was associated with better patient
outcomes. These results are consistent with other pub-
lished studies that established the impact of performance
‘‘bundles’’ on outcomes [32–35].
SSC was a performance improvement process, and not
a dedicated scientiﬁc evaluation of the impact of the
guidelines on clinical outcome. Efﬁcacy was inferred by
observation of change over time, rather than through the
more rigorous approach of a randomized controlled trial.
Thus, conclusions regarding the clinical impact of bundle
elements, or even of the process itself, must be interpreted
with caution. The observation that early detection of
infection and institution of antibiotic therapy led to
improved survival is consistent with both empirical data
[36] and generally held professional opinion. On the other
hand, the observation that achievement of glucose control
is associated with better outcome is not necessarily sup-
ported by recent RCT data [37].
Certain limitations must be considered in interpreting
these ﬁndings. Participation in the process was entirely
voluntary. The hospitals themselves are not necessarily
representative of hospitals that did not participate, and the
generalizability of our ﬁndings is, therefore, speculative.
Further, we do not know whether the patients were a
comprehensive or representative sample of all potentially
Table 2 Cohort characteristics
Site characteristics Subjects (%) Sites (%)
N = 15,022 N = 165
Hospital size
\250 beds 9.9 19.3
250–500 beds 42.3 39.8
[500 beds 47.8 40.9
Teaching status
Teaching 69.2 69.3
Non-teaching 30.8 30.7
ICU Type
Medical 23.3 17.0
Medical/surgical 71.3 78.4
Other 5.4 4.6
Region
Europe 31.1 41.0
North America 58.9 47.0
South America 10.0 12.0
Patient characteristics Subjects
(%)
Hospital
mortality (%)
All 100 34.8
Source
ED 52.4 27.6
ICU 12.8 41.3
Ward 34.8 46.8
Site of infection
Pneumonia 44.4 38.2
UTI 20.8 25.1
Abdominal 21.1 40.8
Meningitis 1.6 23.0
Skin 5.9 28.6
Bone 1.2 31.9
Wound 3.8 32.2
Catheter 4.1 33.9
Endocarditis 1.1 41.0
Device 1.1 42.5
Other infection 12.7 33.1
Baseline acute organ dysfunctions
Cardiovascular
a 85.6 35.4
Pulmonary
b 30.8 41.5
Rena
b 39.5 40.5
Hepatic
b 10.2 45.1
Hematologic
b 25.7 45.0
Number of acute organ
dysfunctions
1 41.8 27.4
2 32.2 34.4
3 17.8 43.7
4 6.4 52.5
5 1.8 63.6
Cardiovascular
No cardiovascular dysfunction 13.5 31.0
Cardiovascular dysfunction no
hypotension
15.0 21.2
Shock
Lactate[4 only 5.4 29.9
Vasopressors only 49.5 36.7
Lactate[4 and vasopressors 16.6 46.1
Total shock 71.5 38.4
a Includes hypotension regardless of response to ﬂuids and elevated
lactate
b Per severe sepsis screening tool, supplemental Fig. 1 online
227eligible subjects at each site. Sites with varying lengths of
participation are included in the analysis. While the rate
of enrollment over time was relatively constant for each
site, the possibility that the types of patients selected
changed over time cannot be excluded. We believe the
data are encouraging and supportive of the Campaign’s
creating beneﬁcial effects both on patient care and patient
outcome. Because the bundles combine physiologic end-
points and processes of care, measures of compliance may
not be precise. However, the improvement in measures
over time probably reﬂects improving compliance,
assuming the case mix was reasonably stable. The inde-
pendent association of these bundle targets with outcome
does not necessarily imply a causal relationship between
the bundle care recommendation and outcomes. Failure to
achieve a target may be indicative of greater severity, so
compliance with the attempt alone may produce the false
impression that compliance is associated with reduced
Table 3 Change in achievement of bundle targets
Initial quarter
achieved (%)
Final quarter
achieved (%)
a P value
compared
to initial
Remaining
quarters
achieved (%)
P value
compared
to initial
Initial care bundle (ﬁrst 6 h of presentation)
Measure lactate 61.0 78.7 B0.0001 72.5 B0.0001
Blood cultures before antibiotics 64.5 78.3 B0.0001 76.3 B0.0001
Broad spectrum antibiotics 60.4 67.9 0.0002 67.0 B0.0001
Fluids and vasopressors 59.8 77.0 B0.0001 71.1 B0.0001
CVP[8 mmHg 26.3 38.0 B0.0001 33.9 B0.0001
ScvO2[70% 13.3 24.3 B0.0001 21.7 B0.0001
All resuscitation measures 10.9 21.5 B0.0001 21.1 B0.0001
Management bundle (ﬁrst 24 h after presentation)
Steroid policy 58.5 73.9 B0.0001 66.8 B0.0001
Administration of drotrecogin alfa policy 47.4 53.5 0.003 49.9 0.02
Glucose control 51.4 56.8 0.0009 55.4 B0.0001
Plateau pressure control 80.8 83.8 0.24 82.6 0.09
All management measures 18.4 25.5 B0.0001 23.3 B0.0001
a Represents the last quarter of data submission from each institution during the 2-year data analysis period, regardless of total number of
quarters of each institution’s participation
Fig. 2 Compliance and mortality change over time: a change in the
percentage of patients compliant with all elements of the resusci-
tation bundle (dotted line) and the management bundle (solid line)
over 2 years of data collection (*P\0.01 compared to ﬁrst
quarter). Note that both Y axes are truncated at 40% to emphasize
relative change over time as opposed to absolute change; b change
in hospital mortality over time (*P\0.01 compared to ﬁrst
quarter)
Table 4 Multivariable mortality prediction model
Variable OR 95% CI P value
Admission source
Ward compared to ED 1.87 [1.73, 2.02] B0.0001
ICU compared to ED 2.25 [2.02, 2.51]
Pneumonia as source of sepsis
compared to other infections
1.37 [1.27, 1.48] B0.0001
Organ dysfunction at presentation
Cardiovascular 1.39 [1.26, 1.55] B0.0001
Respiratory 1.23 [1.14, 1.34] B0.0001
Hematologic 1.61 [1.48, 1.75] B0.0001
Hepatic 1.28 [1.14, 1.75] B0.0001
Renal 1.40 [1.30, 1.51] B0.0001
Site duration in campaign
Per quarter 0.97 [0.96, 0.99] 0.0006
Model ﬁt statistics: C = 18.1 with 18 df, P = 0.34, log-likelihood
R
2 sq 36.6%, a v
2 dispersion of 1.04
228mortality. Therefore, attention to adjustment for severity
of patient illness at time of enrollment should be
attempted.
Similarly, failure to achieve blood glucose control
despite attempting to do so is not the same as failure to
make the attempt. Attempting to discriminate failure to
achieve a target versus patient responsiveness adds a layer
of complexity and subjectivity to the scoring process that
would be difﬁcult to validate. Nevertheless, because
patient responsiveness is unlikely to change over time, the
scoring should reﬂect each hospital’s improvement
attempts. By combining a number of elements in the care
bundles, the Campaign sought to maximize outcome
improvement. At the same time, such an approach com-
promises measuring the effect of individual elements.
The fact that performance improvement studies are
susceptible to general trends in the change in mortality
and clinical practice patterns over time is another poten-
tial limitation of the study, but the variable start times for
each site established that such effects were unlikely to
explain the improvement in mortality. The baseline
mortality rate for sites entering at variable times
throughout the 2-year study period did not change. For-
mal severity scores were not obtained for patients entered
into the database due to limited personnel resources in the
absence of external site funding and conﬁdentiality con-
cerns. Therefore, decreasing mortality seen over the 2-
year initiative might be explained by the enrollment of
less severely ill patients over time, in spite of the static
baseline center mortality. To control for entry of less
severely ill patients in the database over time as the rea-
son for decreasing mortality, severity was assessed based
on variables linked to patient mortality that were available
in the database (Table 4). When mortality was adjusted
accordingly, although the magnitude of the effect was
slightly reduced, it remained statistically signiﬁcant.
In conclusion, the results of this study demonstrate
that the use of a multifaceted performance improvement
initiative was successful in changing sepsis treatment
behavior as evidenced by a signiﬁcant increase in com-
pliance with sepsis performance measures. This
compliance was associated with a signiﬁcant reduction in
hospital mortality in patients with severe sepsis and septic
shock over the duration of the 2-year study, but the study
design does not allow us to say, with certainty, whether
this was due to some or all bundle elements, increased
awareness of severe sepsis, or other unrelated factors.
Many unanswered questions remain that could provide
direction for future research, including the mortality trend
in hospitals that have not implemented the bundles, and
conﬁrmation of which components of the bundles reduce
mortality. These results are consistent with an earlier
report from Spain [38], and extend the ﬁndings of that
study by suggesting that the improvement in achievement
of bundle targets and association with improved outcome
is sustained over time and is demonstrated across a wide
number of countries and settings. Professional societies
frequently generate evidence-based clinical practice
guidelines, but efforts to disseminate such guidelines have
rarely been of a scale comparable to this Campaign. The
results of this study should encourage similar efforts to
implement guidelines as a means to improve outcomes.
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